7th Nov 2016 09:41
LONDON (Alliance News) - Avacta Group PLC on Monday said it has appointed immuno-oncology and cancer stem cell specialist Gerald Evan to its therapeutics scientific advisory board.
The group, which has developed Affimer biotherapeutics and research re-agents, said Evan's research into the molecular basis of cancer will support its development of oncology biotherapeutics based on its Affimer technology.
Evan was elected as the Sir William Dunn chair of biochemistry and head of biochemistry at the University of Cambridge in 2009, and is currently a fellow of the Royal Society, the UK Academy of Medical Sciences and the European Molecular Biology Organisation.
"Evan's deep knowledge of the molecular mechanisms of cancer will be a great asset to the company and in particular his pioneering work in the area of cancer stem cell biology could help create novel and highly valuable Affimer therapies in this emerging area," said Avacta Chief Executive Alastair Smith.
Shares in Avacta were down 1.0% at 93.05 pence on Monday morning.
By Hannah Boland; [email protected]; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group